Related Experiment Video
Updated: Jun 12, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
The quest for new anticoagulants: from clinical development to clinical practice
Stavros Apostolakis1, Gregory Y H Lip, Deirdre A Lane
1Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.
Abstract:
The vitamin K antagonists (VKAs) have been the standard treatment of thromboembolic diseases for more than 50 years. They have been proved effective and safe under optimal settings; however, the long-term application of VKAs has been considered problematic and challenging for both patients and physicians due to their narrow therapeutic window, the frequent drug to drug interactions and the need for regular monitoring. Novel anticoagulants that selectively block specific pathways of the coagulation cascade have demonstrated efficacy and safety without the need of intensive monitoring. Several novel anticoagulants are already licensed for the prevention and treatment of thromboembolic disease while others are in advanced stages of clinical development. This review summarizes data derived from recently published clinical trials and discusses the present and the future of oral anticoagulation.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Clinical Trials: Overview
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clinical Trials
There are four phases in a clinical trial. A phase one...
